The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).
At least 18 years of age inclusive, at the time of signing the informed consent form (ICF)
Have a palmoplantar pustulosis (PPP) diagnosis for at least 24 weeks prior to the Screening Visit
Have PPPASI ≥12 at the Screening Visit and Baseline Visit
Have PPP-IGA ≥3 at the Screening Visit and Baseline Visit
Has PPP symptoms which improve significantly between the Screening Visit and Baseline Visit, defined as a reduction in the PPPASI score
Has the following: palmoplantar PSO (plaque PSO on palms/soles), guttate PSO, erythrodermic PSO (EP), generalized pustular PSO (GPP), Acrodermatitis continua of Hallopeau (ACH), atopic dermatitis, dyshidrotic eczema or chronic hand eczema.
Has drug-induced PSO (eg, first onset or current exacerbation due to beta blockers, calcium channel inhibitors, lithium, or tumor necrosis factor [TNF] inhibitor) or drug-induced pustular PSO (eg, acute generalized exanthematous pustulosis, acute localized exanthematous pustulosis)
Has cutaneous lesions that may interfere with the evaluation of the affected area and/or evaluation of the severity of PPP